GSK
GlaxoSmithKline PLC
48.20$
-2.4%
vs. previous close
Closing price · As of: Sep 30, 2026
Statements
Cash Flow
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -50.4% | +152.9% | +6.5% | +21.7% | -4.8% | +5.2% | -5.8% | -6.9% | +6.6% | -16.9% | +9.0% | |
| – | -8.1% | -0.1% | +60.2% | -40.9% | +69.9% | -79.2% | +304.5% | -9.0% | +24.1% | -10.5% | +44.9% | |
| – | +10.8% | -13.3% | +4.4% | +8.1% | +1.4% | +4.4% | -3.7% | -5.7% | -11.3% | +12.1% | +8.7% | |
| – | -34,232.6% | – | +2,463.4% | -23.2% | -78.9% | -43.3% | -72.4% | -8,044.8% | – | – | – | |
| – | +186.8% | -83.9% | -356.3% | – | – | -77.4% | -494.2% | – | -492.6% | – | -129.1% | |
| – | +8.6% | +23.7% | -6.4% | -18.4% | +20.4% | +3.5% | +30.9% | -23.0% | -27.7% | +82.6% | -55.8% | |
| – | – | -121.0% | +13.7% | +7.6% | +244.8% | – | -182.2% | +393.6% | -72.6% | -48.9% | +365.6% | |
| – | +0.8% | +25.2% | -19.5% | +0.5% | +0.7% | +0.6% | +0.6% | -13.3% | -19.4% | -12.5% | +2.6% | |
| – | -70.3% | -25.3% | -12.2% | – | +17.2% | -90.3% | -264.5% | – | -888.0% | – | -6,910.0% | |
| – | -11,055.2% | – | -861.5% | – | -56.7% | -220.5% | -47.8% | +118.3% | -50.9% | -50.8% | – | |
| – | +31.9% | -10.0% | -0.2% | +0.1% | -71.2% | +450.7% | -25.1% | – | -837.4% | -22.1% | -66.3% | |
| – | – | -160.4% | – | – | +52.8% | -42.1% | -434.8% | – | – | – | -137.8% | |
| – | -80.5% | +520.5% | +13.8% | +40.5% | -11.6% | +5.9% | -19.0% | +2.5% | +21.6% | -42.9% | +63.1% |
Data as of: September 30, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.